Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

Sponsor
Siriraj Hospital
Study ID
NCT04970251
Status
Completed

Conditions

  • Glaucoma Secondary to Eye Inflammation
  • Intraocular Pressure
  • Neovascular Glaucoma
  • Vascular Endothelial Growth Factor Overexpression

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Aflibercept Ophthalmic — DRUG
    Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.

Study Details

Purpose: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG). Setting: Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Study design: Prospective interventional case series Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC if indicated. Best-collected visual acuity (BCVA), intraocular pressure (IOP), surgical complications, and number of anti-glaucoma medications were collected.

Key Dates

First listed
Jul 21, 2021
Start date
Nov 1, 2018
Status verified
Jul 2021
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Intraocular pressure [ Time Frame: Post-operative on day 1st ]

Related Studies